Vaxart, Inc., trading as VXRT on NASDAQ, is a publicly-traded company with a market capitalization of 130 mln USD. Based on its revenue data for the last 5 quarters, it seems that the company has not been able to generate significant income from its operations. For example, in the most recent quarter ending December 31 2021, Vaxart reported revenues of 74000 USD.
The estimated revenue for this quarter was 170000 USD and in previous quarters, it had zero revenue. This shows that the company’s income has not been consistent and does not appear to be growing significantly over time. Furthermore, Vaxart’s earnings per share (EPS) have been negative for all five quarters studied here. In terms of stock price performance, in spite of some positive fluctuations over recent weeks, the price is still substantially lower than its high point of 5.43 USD that occurred in May 2021.
Overall, Vaxart’s financial situation appears weak evidenced by its low revenues and negative EPS results which might explain its underperformance compared to other stocks in the same industry. Going forward, it will be important for the company to focus on generating more income from their operations if they want to improve their financial outlook.
